ProCE Banner Activity

Phase III CheckMate 7FL: Biomarker Analysis of Addition of Nivolumab vs Placebo to Neoadjuvant CT and Adjuvant ET in High-Risk ER+/HER2- EBC

Conference Coverage

In this exploratory analysis of the CheckMate 7FL trial, clinical efficacy with the addition of nivolumab vs placebo was greatest among patients with high-risk ER+/HER2- breast cancer whose tumors were PD-L1 positive, had stromal tumor-infiltrating lymphocytes, and expressed low levels of estrogen and/or progesterone receptors.

Released: December 08, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.